In a rabbit study, Children's Hospital of Philadelphia and University of Pennsylvania researchers rebuilt narrowed infant airways with a scaffold seeded with the patient's own cartilage cells, the first engineered graft ready for implant in weeks rather than months.
A team at Children's Hospital of Philadelphia and the University of Pennsylvania has shown in rabbits that a cartilage graft built from a patient's own cells, seeded onto a scaffold made from pig knee cartilage, can rebuild a narrowed infant airway faster and without the donor-site toll of the current rib-cartilage standard. The result, published in Nature Communications, is preclinical, not yet a treatment for babies. It is the first demonstration that engineered cartilage can fit inside the timing window pediatric airway surgeons actually work in.
The condition is severe subglottic stenosis, a narrowing of the airway just below the vocal cords and above the trachea. It affects roughly 1.5 percent of the more than 200,000 infants intubated each year in the United States, according to figures cited in the Nature Communications paper, or about 20,000 babies annually. The standard repair, laryngotracheal reconstruction, uses cartilage harvested from the child's own rib. In small patients that approach runs into three limits the paper names: harvesting a rib adds another wound to an already fragile child, the available tissue volume is often too small to widen the airway adequately, and the surgery has to wait for the child to grow enough to donate the graft.
The new method, described in the same Nature Communications paper, starts with meniscus cartilage from pigs, the tough cushioning wedge of tissue inside the knee. Because pigs are slaughtered for food in vast numbers, meniscus is an abundant waste stream with no donor-shortage problem. The team strips out the original pig cells and the blood-vessel and elastin scaffolding, leaving behind a structural matrix. They then seed that matrix with cartilage progenitor cells taken from the patient's own ear. The seeded graft is fully recellularized in three days and reaches structural and functional maturity suitable for implant within three weeks of chondrogenic differentiation, the paper reports. That timeline fits inside the one-to-two-month clinical window pediatric airway surgeons typically have. Engineered cartilage from prior approaches generally needed about six months to mature, far too long for an infant who cannot breathe.
In a rabbit model, the graft expanded the airway, was reepithelialized by the host, formed new cartilage, and integrated with the animals' native laryngotracheal cartilage over three months, with no adverse events reported. According to the Nature Communications paper, the meniscus-based graft outperformed autologous costal cartilage, the current standard of care, on those measured endpoints. Genetic Engineering & Biotechnology News summarized the work as a step toward a personalized pediatric airway graft.
The work was co-led by Riccardo Gottardi, who leads a bioengineering and biomaterials laboratory at Penn's Perelman School of Medicine with a joint appointment at Children's Hospital of Philadelphia, and Ian Jacobs, medical director of CHOP's Center for Pediatric Airway Disorders in the Division of Otolaryngology. First author Paul Gehret, a former Gottardi lab member, is the lead on the published study. Jacobs told GEN that the research "could overcome the autograft-associated limitations" of current pediatric airway surgery and hinted it may extend to other cartilage-graft indications.
What stands between this rabbit result and the first child is regulatory preparation and a first-in-child trial. The paper itself notes the work must be "further validated prior to proposing the procedure for patients." That milestone, not a clinical rollout, is the next concrete step to watch.